Combination of dual-targeted therapies and chemotherapy shows high response rates in BRAF-mutated metastatic colorectal cancer: Clinical trial finds 60.9% overall response rate (ORR) with combination of encorafenib, cetuximab and mFOLFOX6 compared to 40% with standard-of-care (SOC) treatment.